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Background: The prevalence of metastatic bone disease in the US population is not well 
understood. We sought to estimate the current number of US adults with metastatic bone disease 
using two large administrative data sets.
Methods: Prevalence was estimated from a commercially insured cohort (ages 18–64 years, 
MarketScan database) and from a fee-for-service Medicare cohort (ages $65 years, Medicare 
5% database) with coverage on December 31, 2008, representing approximately two-thirds 
of the US population in each age group. We searched for claims-based evidence of metastatic 
bone disease from January 1, 2004, using a combination of relevant diagnosis and treatment 
codes. The number of cases in the US adult population was extrapolated from age- and sex-
specific prevalence estimated in these cohorts. Results are presented for all cancers combined 
and separately for primary breast, prostate, and lung cancer.
Results: In the commercially insured cohort (mean age = 42.3 years [SD = 13.1]), we identi-
fied 9505 patients (0.052%) with metastatic bone disease. Breast cancer was the most common 
primary tumor type (n = 4041). In the Medicare cohort (mean age = 75.6 years [SD = 7.8]), we 
identified 6427 (0.495%) patients with metastatic bone disease. Breast (n = 1798) and prostate 
(n = 1862) cancers were the most common primary tumor types. We estimate that 279,679 (95% 
confidence interval: 274,579–284,780) US adults alive on December 31, 2008, had evidence of 
metastatic bone disease in the previous 5 years. Breast, prostate, and lung cancers accounted 
for 68% of these cases.
Conclusion: Our findings suggest that approximately 280,000 US adults were living with 
metastatic bone disease on December 31, 2008. This likely underestimates the true frequency; 
not all cases of metastatic bone disease are diagnosed, and some diagnosed cases might lack 
documentation in claims data.
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Introduction
Bone is a common site of metastatic cancer.1,2 Bone metastases occur in most tumor 
types but are most prevalent in cancers of the breast, prostate, and lung.3 These bone 
lesions can cause serious skeletal complications, including spinal cord or nerve root 
compression, bone surgery, hypercalcemia of malignancy, pathologic fractures, and 
severe bone pain requiring palliative radiotherapy,4,5 all of which can significantly 
compromise quality of life6–10 and may negatively affect survival.11,12 Palliation of 
pain, prevention of skeletal complications, and maintenance of quality of life are the 
primary objectives in managing patients with metastatic bone disease.5
A diagnosis of malignant bone disease generally represents an incurable   cancer. 
However, the clinical course can be prolonged. Based on recent research using 
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  population-based and medical registries in Denmark, 1- and 
3-year cumulative survival in breast cancer patients diag-
nosed with bone metastases was 59% and approximately 
22%,13 respectively. Similarly, 1- and 3-year cumulative 
survival in prostate cancer patients diagnosed with bone 
metastases was 47% and approximately 9%,14 respectively. 
These data demonstrate that for some patients, metastatic 
bone disease is a chronic condition that must be carefully 
managed.
To better understand the burden of metastatic bone 
disease in the United States, current and reliable estimates 
of prevalent cases are important. Estimates of incidence 
rates and subsequent survival in a population-based setting 
are available,13–17 but current prevalence data are scant. We 
sought to estimate the current number of patients with meta-
static bone disease in the US adult population by applying 
a claims-based definition of metastatic bone disease to two 
large administrative data sets.
Methods
Data sources and study participants
Two data sources were used in this analysis: the MarketScan 
database and the Medicare 5% database. MarketScan is a 
large commercial claims and encounters database of spe-
cific health services records, demographics, and enrollment 
information for employees and their dependants selected 
from employer health insurance plans. It includes informa-
tion on diagnoses, procedures performed and reimbursed by 
commercial insurance, and dates of service.
The Medicare 5% database is a random sample of all 
Medicare beneficiaries. It includes the annual denominator 
file, which contains information on demographics and enroll-
ment in Medicare and managed care organizations (health 
maintenance organizations [HMO]) for each beneficiary; 
and the annual claims-based Standard Analytic Files, which 
contain Part A institutional and Part B physician/suppliers 
files. Claims-based files include information on diagnoses, 
procedures performed and reimbursed by Medicare, and 
dates of service.
Two point-prevalent study cohorts were assembled of 
beneficiaries with insurance coverage on December 31, 2008. 
The first included employees and their dependants enrolled 
in fee-for-service plans through their employers and aged 
18–64 years on December 31, 2008 (“commercially insured” 
cohort). The second included Medicare Parts A and B ben-
eficiaries not enrolled in HMOs (“fee-for-service Medicare” 
cohort), residing in the 50 states and District of Columbia 
and aged $65 years on December 31, 2008. We examined 
all available claims for each cohort member in the preceding 
5 years (January 1, 2004, through December 31, 2008) for 
evidence of metastatic bone disease.
Identification of metastatic bone disease, cancer, and 
cancer type
Patients were identified as having metastatic bone disease by 
(1) at least one inpatient claim or two outpatient claims on dif-
ferent days within any 12-month interval, carrying the Inter-
national Classification of Diseases, Ninth   Revision, Clinical 
Modification (ICD-9-CM) diagnosis code for secondary 
malignant neoplasm of bone or bone marrow (198.5); or (2) 
at least one claim carrying Healthcare Common   Procedure 
Coding System codes for intravenous (IV) bisphosphonates 
zoledronic acid (Zometa, J3487) or pamidronate (J2430) 
with at least one qualifying code on the same claim. Quali-
fying codes included the ICD-9-CM diagnosis codes for 
primary cancer (see Table 1); metastatic cancer in lymph 
nodes (196.xx), respiratory and digestive systems (197.xx), 
and other sites including bone and bone marrow (198.xx); 
and V codes for encounters for antineoplastic chemotherapy 
(V58.11) and immunotherapy (V58.12). The earliest date of 
Table 1 International Classification of Diseases, Ninth Edition, 
Clinical Modification diagnosis codes used to identify cancer types
Cancer types Diagnosis codes
Head and neck 140-14999
Esophagus 150-15099
Stomach and small intestine 151-15299
Colon and rectum 153-15489
Liver 155-15529
Gallbladder 156-15699
Pancreas 157-15799
Retroperitoneum and peritoneum 158-15899
Spleen 159-15999
Lung 162-16399
Other respiratory 160-16199, 164-16599
Bone 170-17099
Connective and soft tissue 171-17199
Melanoma 172-17299
Female breast 174-17499
Male breast 1750 or 1759
Sarcoma 176-17699
Gynecologic 179-18499
Prostate 185
Other genitourinary 186-18999
Central nervous system 190-19299
Endocrine 193-19499
Non-Hodgkin’s lymphoma 200-20099, 202-20299
Hodgkin’s lymphoma 201-20199
Multiple myeloma 203-20380
Leukemia 204-20891
Ill-defined 195-19599, 199-19999
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bone metastasis code or qualifying IV bisphosphonate code 
was defined as the bone metastasis index date.
These patients were also required to have claims-based 
evidence of primary cancer during a 12-month interval from 
6 months before to 6 months after the bone metastasis index 
date. Cancer type was defined by presence of the ICD-9-CM 
diagnosis code for a specific cancer type (Table 1) on at least 
one inpatient claim or two outpatient claims on   different 
days in the 12-month interval. We included   multiple 
myeloma and primary bone malignancies in our study 
because, while we recognize that these are intrinsic diseases 
of the bone, any malignancies with invasion of bone (bone 
metastases from solid tumors, multiple myeloma, etc) share 
substantial clinical consequences and may be indicated for 
and benefit from similar management. Further, we wanted 
our analysis to be consistent with other reports of the burden 
of metastatic bone disease18 for comparison purposes. Solid 
tumors that most frequently metastasize to bone (breast 
cancer [female only], prostate cancer, and lung cancer) 
were of interest in this study. When there was claims-
based evidence of more than one of these three cancer 
types, the following algorithm was applied to identify a 
single type: (1) if there were   bisphosphonate claims, the 
cancer type coded most frequently on these claims was 
chosen; (2) if there were no bisphosphonate claims, the 
cancer type coded most frequently on all claims during the 
12-month interval was chosen.
Estimation of number of prevalent cases 
in the national commercially insured 
population and fee-for-service Medicare 
population
The number of prevalent cases of metastatic bone disease 
in the national commercially insured population aged 
18–64 years was extrapolated with person-level weights 
derived from the Medical Expenditure Panel Survey and 
provided by the data vendor.19 The number of prevalent 
cases in the national fee-for-service Medicare population 
aged $65 years was extrapolated by multiplying observed 
estimates in the 5% sample by twenty.
Estimation of the number of prevalent 
cases in the US adult population
To account for US citizens not represented in the com-
mercially insured or the Medicare populations, the number 
of prevalent cases estimated in these two data sources was 
extrapolated to the entire US adult population by   applying 
age- and sex-specific prevalence estimates to the 2008 US 
Census population.20 Age- and sex-specific prevalence 
  estimates were produced by extrapolating the observed 
estimates for each age (18–44, 45–64, 65–74, 75–84, 
and $85 years) and sex combination to the commercially 
insured population aged 18–64 years and the fee-for-service 
  Medicare population aged $65 years. Multiplying the 
age- and sex-specific prevalence estimates by counts of US 
populations in each category produced the total number of 
cases in each category. Summing these age- and sex-specific 
cases produced an estimated total number of patients living 
with metastatic bone disease in the US adult population as 
of December 31, 2008. This analysis was conducted for all 
cancers combined and then repeated for breast, prostate, and 
lung cancers.
All analyses were conducted using SAS software (version 
9.1; SAS Institute Inc, Cary, NC).
Results
Demographic characteristics
The commercially insured cohort included 18,218,583 
enrollees who met the inclusion criteria; 52.4% were aged 
18–44 years and 47.7% were men. The fee-for-service 
Medicare cohort included 1,297,538 beneficiaries who met 
the inclusion criteria; 50.6% were aged 65–74 years, 34.5% 
were aged 75–84 years, and 42.2% were men.
Number of patients with metastatic bone 
disease in the study cohorts
Table 2 presents the number of patients meeting the case defi-
nition for metastatic bone disease and the distribution of case 
definition sources in each study cohort. In the commercially 
insured cohort, we identified 9505 patients (0.052% of the 
cohort) living with metastatic bone disease on December 31, 
2008. Of the solid tumors examined separately, breast   cancer 
was the most common primary tumor type (n = 4041). In the 
Medicare cohort, we identified 6427 (0.495%) patients with 
metastatic bone disease. Breast (n = 1798) and prostate 
(n = 1862) cancers were the most common primary tumor 
types.
Compared with elderly patients, younger patients with 
metastatic bone disease were more often identified from 
drug codes only (commercially insured: 27.9%, Medicare: 
20.1%), less frequently identified from the diagnosis codes 
only (commercially insured: 28.9%, Medicare: 37.0%), and 
about equally as often identified from both drug and diagno-
sis codes (commercially insured: 43.3%, Medicare: 43.0%). 
Case definition sources varied considerably across the three 
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cancer types of interest; the proportion of cases identified by 
diagnosis code alone was highest for lung cancer and lowest 
for breast cancer.
Estimated number of prevalent cases  
of metastatic bone disease in the national 
commercially insured population and  
fee-for-service Medicare population
By applying the person-level weights, we estimated a 
total of 60,411 (95% confidence interval [CI]: 59,134–
61,689) patients living with metastatic bone disease on 
December 31, 2008, among 120.7 million commercially 
insured persons aged 18–64 years in the United States; 
patients with breast, prostate, or lung cancer accounted 
for 64% of prevalent cases of metastatic bone disease. 
Among the 26 million fee-for-service Medicare enrollees 
in the United States, 128,540 (95% CI: 125,485–131,595) 
patients were living with metastatic bone disease; 69% of 
cases occurred in patients with the specified cancer types. 
Table 3 presents estimates of prevalent cases of metastatic 
bone disease in these two large components of the insured 
US adult population for all cancers and by the three specific 
types of interest.
Estimated number of prevalent cases  
of metastatic bone disease in the US  
adult population
Table 3 also presents estimates of prevalent cases of meta-
static bone disease for the entire US adult population based 
on the age- and sex-specific prevalence estimates as shown 
in Table 4. We estimated that a total of 279,679 (95% CI: 
274,579–284,780) US adults alive on December 31, 2008, 
had evidence of metastatic bone disease in the previous 
5 years. Of the three cancer types examined separately, 
female breast cancer was the most common primary cancer 
type, accounting for about one-third of total metastatic bone 
disease cases in the US adult population (n = 90,904; 95% 
CI: 88,095–93,714). Prostate cancer was the second most 
common (n = 62,841; 95% CI: 60,253–65,429), and lung 
cancer was the least common of the specific cancer types 
examined (n = 35,222; 95% CI: 33,415–37,030). These three 
cancer types combined accounted for 68% of total metastatic 
bone disease cases.
Discussion
This descriptive study estimated the number of point-
prevalent cases of metastatic bone disease in the US adult 
Table 2 Number of patients meeting the metastatic bone disease case definition in the commercially insured and Medicare 5% sample 
cohorts and case definition sources, all cancers and by specific cancer types
Cancer type Commercially insured cohort (n = 18,218,583) Medicare 5% sample cohort (n = 1,297,538)
n (%) Definition sourcesa n (%) Definition sourcesa
Diagnosis  
codes only
Drug  
codes only
Both Diagnosis  
codes only
Drug  
codes only
Both
All cancers 9505 (0.052) 28.9 27.9 43.3 6427 (0.495) 37.0 20.1 43.0
Female breast 4041 (0.022) 17.6 23.9 58.5 1798 (0.139) 27.2 18.5 54.3
Prostate 776 (0.004) 31.6 15.7 52.7 1862 (0.144) 40.3 11.9 47.8
Lung 1253 (0.007) 49.2 10.2 40.6 795 (0.061) 57.5 6.9 35.6
Other 3435 (0.019) 34.1 41.7 24.3 1972 (0.152) 34.5 34.5 31.0
Note: aPercent of row total.
Table 3 Estimated number of prevalent cases of metastatic bone disease in the national commercially insured population aged 18–64 
years, the national fee-for-service Medicare population aged $65 years, and the US adult population on December 31, 2008, all cancers 
and by specific cancer types
Cancer type Commercially insured,  
ages 18–64 years 
(n = 120,694,145)
Fee-for-service Medicare,  
ages $65 years 
(n = 25,950,760)
US adult populationa 
(n = 230,118,000)
All cancers 60,411 (59,134–61,689) 128,540 (125,485–131,595) 279,679 (274,579–284,780)
Female breast 25,754 (24,911–26,596) 35,960 (34,341–37,579) 90,904 (88,095–93,714)
Prostate 4,969 (4,609–5,329) 37,240 (35,593–38,887) 62,841 (60,253–65,429)
Lung 7,879 (7,421–8,337) 15,900 (14,823–16,977) 35,222 (33,415–37,030)
Other 21,809 (21,046–22,573) 39,440 (37,745–41,135) 90,712 (87,843–93,580)
Notes: Data presented as estimated number of patients with metastatic bone disease (95% confidence interval). aUS Census 2008.
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population on December 31, 2008, using a large commercial 
insurance claims database and the Medicare 5% sample 
  database. Our findings suggest that approximately 280,000 
US adults were living with metastatic bone disease on 
December 31, 2008, with 68% of cases occurring in patients 
with primary breast, prostate, or lung cancer.
To our knowledge, Schulman and Kohles18 published 
the only other study aimed at describing the burden of 
metastatic bone disease in the US population in terms of 
prevalence. The similar magnitude of our national point-
prevalence estimate (279,679) and the Schulman and Kohles18 
period-prevalence estimate of the size of the US population 
with metastatic bone disease between 2000–2004 (256,137) 
obscures important differences in numbers by cancer type. 
Compared with their estimates, ours were 30% higher for 
breast cancer, 32% higher for prostate cancer, 5% lower 
for lung cancer, and 11% lower for all other cancer types 
combined. The study methodologies differ in important 
ways beyond estimation of point- versus period-prevalence. 
Schulman and Kohles18 included pediatric patients (though 
few cases were identified) and used prevalence estimates for 
Medicare enrollees with supplemental employer-paid insur-
ance to extrapolate to the full Medicare population. How well 
this Medicare subset represents the entire Medicare population 
is debatable. We limited our extrapolation to the Medicare 
fee-for-service population, having studied a random sample of 
this population in the Medicare 5% data set. Rather than make 
the assumption that the overall prevalence of metastatic bone 
disease in the population not covered by commercial insurance 
or by Medicare was the same as in the commercially insured 
or Medicare population, we took the approach of calculat-
ing observed age- and sex-specific prevalence, based on our 
extrapolation to the commercially insured (ages 18–64 years) 
and fee-for-service Medicare (aged $65 years) populations, 
and applied these estimates to counts of the US adult popula-
tion in each stratum from the US Census.
Another key difference is that we included bisphosphonate 
treatment in the case definition of bone metastasis. Schulman 
and Kohles18 identified patients with the first documented 
diagnosis of primary cancer, and followed claims over time 
for evidence of metastatic bone disease defined by at least 
one ICD-9-CM code for metastatic bone disease (198.5) or 
by a primary diagnosis code for a cancer type other than 
bone cancer and a secondary diagnosis code for bone cancer 
(170.xx). We assessed whether cohort members met a claims-
based definition for metastatic bone disease before identify-
ing cancer type. Our case definition required one inpatient 
claim with an ICD-9-CM code of 198.5 or two outpatient 
claims with this code on different days within any 1-year 
interval between 2004–2008 (to avoid including patients 
who were tested to rule out metastatic bone disease and had 
no further claims evidence of metastatic bone disease). We 
also included in the case definition one or more claims for IV 
zoledronic acid (Zometa) or pamidronate, provided the claim 
included a code for cancer or cancer treatment. The only 
licensed indications for these two therapies in cancer patients 
are bone lesions from solid tumors or multiple myeloma and 
hypercalcemia of malignancy, which is relatively rare and 
even rarer in the absence of bone metastasis.21 Our decision 
to include bisphosphonate treatment in the case definition 
was motivated by concern that use of diagnosis codes alone 
to identify metastatic bone disease results in relatively low 
sensitivity.22
The strength of this study is that the data sets used 
included representative samples of two large components of 
the US adult population. The commercial claims database is 
Table 4 Age- and sex-specific prevalence estimates of metastatic bone disease and distribution of age and sex in the US adult 
population
Sex Age, years Insured  
population,a n
Prevalence of metastatic bone disease (standard error), per 10,000 
population
US 
population,b n
All cancers Female breast Prostate Lung Other
Men 18–44 32,978,252 0.64 (0.04) 0.03 (0.01) 0.09 (0.02) 0.52 (0.04) 57,522,000
45–64 26,686,875 6.96 (0.14) 1.82 (0.07) 1.35 (0.06) 3.79 (0.11) 38,104,000
65–74 6,043,760 41.99 (1.18) 19.33 (0.80) 7.05 (0.48) 15.62 (0.72) 9,265,000
75–84 3,686,380 73.41 (1.99) 45.74 (1.57) 8.30 (0.67) 19.37 (1.02) 5,336,000
$85 1,210,060 90.74 (3.86) 71.90 (3.43) 4.30 (0.84) 14.54 (1.55) 1,864,000
Women 18–44 32,729,023 1.41 (0.06) 0.99 (0.05) 0.10 (0.02) 0.33 (0.03) 55,666,000
45–64 28,299,994 12.40 (0.19) 7.96 (0.15) 1.29 (0.06) 3.15 (0.10) 39,956,000
65–74 7,076,540 40.39 (1.07) 22.53 (0.80) 6.25 (0.42) 11.62 (0.57) 10,858,000
75–84 5,269,160 50.63 (1.38) 27.40 (1.02) 5.43 (0.45) 17.80 (0.82) 7,689,000
$85 2,664,860 37.00 (1.66) 20.94 (1.25) 2.93 (0.47) 13.13 (0.99) 3,858,000
Notes: aNational commercially insured population aged 18–64 years and fee-for-service Medicare population aged $65 years; bUS Census 2008.
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one of the larger in the US and contains data on approximately 
24 million employees and their dependants aged younger than 
65 years who have health insurance through their employers. 
Approximately 18 million individuals were included in our 
study. Weights contained in this database allowed us to 
project estimates of bone metastasis prevalence to approxi-
mately 121 million US adults aged 18–64 years covered by 
employer-sponsored insurance, representing 63% of the total 
US population of this age range. The Medicare 5% sample 
database is essentially a random sample of approximately 
44 million Medicare beneficiaries. Estimates from approxi-
mately 1.3 million individuals eligible for our study were 
projected to 26 million Medicare fee-for-service enrollees 
with Part A and Part B coverage, accounting for two-thirds 
of the US population aged $65 years. Furthermore, age and 
sex distribution in the two projected populations were similar 
to the total US adult population aged 18–64 and $65 years, 
respectively.
Several limitations should be noted when interpreting our 
findings. While we examined claims from 2004–2008 for 
evidence of metastatic bone disease, estimates of prevalence 
in this study cannot be properly interpreted as measures of 
the prevalence of 5-year history of metastatic bone disease, 
because not all individuals included in this study were continu-
ously insured within the data sets studied. Of the commercially 
insured enrollees, 83.4%, 46.0%, 21.6%, 14.6%, and 11.1% 
had at least 1 year, 2 years, 3 years, 4 years, and 5 years of con-
tinuous coverage, respectively. The corresponding distribution 
of the fee-for-service Medicare enrollees was 93.3%, 86.1%, 
79.7%, 74.2%, and 68.9%. Patients with relatively shorter 
duration of insurance coverage without claims evidence for 
metastatic bone disease may have had evidence of metastatic 
bone disease during the period without insurance coverage. 
The probable effect of examining less than 5 years of claims 
is underestimation of prevalence, as persons may be falsely 
identified as not having a history of metastatic bone disease. 
To explore this issue, we performed a post hoc analysis. We 
estimated separately in each cohort the crude probability 
of de novo evidence of metastatic bone disease in calendar 
year Y, given no evidence of metastatic bone disease from 
Y + 1 to 2008 and continuous enrollment from Y to 2008, 
for Y = 2004, 2005, 2006, and 2007. We used these prob-
abilities to inflate prevalence estimates, such that the modified 
estimates could be interpreted as (extrapolated) measures of 
the prevalence of 5-year history of metastatic bone disease. 
We found that the number of persons with a 5-year history of 
metastatic bone disease could be as high as 322,180 (versus 
279,679 in Table 3) US adults. These   modified estimates 
may be high, as the most common causes of non-continuous 
enrollment – a recent employment change in the non-elderly 
and a recent 65th birthday in the elderly – likely predict the 
absence of metastatic bone disease.
Second, not all diagnoses of metastatic bone disease result 
in corresponding claims codes. Few studies have examined 
the validity of using diagnosis codes to identify metastatic 
bone disease. The only such study we are aware of was done 
in Denmark and evaluated use of the ICD-10 code for meta-
static bone disease (C79.5).22 Using the National Registry of 
Patients database and data from medical chart reviews as the 
gold standard, Jensen et al22 found relatively low sensitivity 
(0.44 [95% CI: 0.30–0.60] for prostate cancer and 0.32 [95% 
CI: 0.13–0.57] for breast cancer) and very high specificity. 
These results may not be applicable to the US experience. 
The ICD-10 diagnosis code set is substantially different in 
structure and concept from the ICD-9 code set, which is still in 
use in the United States. In addition, the coding practices may 
differ. Our use of codes for IV bisphosphonates relevant to 
treatment of metastatic bone disease to supplement the diagno-
sis code should help improve sensitivity, but this also presents 
limitations. For example, patients with kidney dysfunction or 
known risk factors for osteonecrosis of the jaw may not be 
candidates for bisphosphonate therapy. Additionally, patients 
who underwent orthopedic procedures or palliative radiation 
for a malignant fracture may not be identified by the codes 
used. Ultimately, the sensitivity and specificity of our claims-
based definition of metastatic bone disease remains unknown 
until a validation study is performed.
Third, the age- and sex-specific prevalence estimates we 
applied to the US Census counts in each stratum were based 
on results from analysis of the commercially insured and fee-
for-service Medicare populations. Prevalence of metastatic 
bone disease in the remainder of the adult population may 
differ from prevalence in the commercially insured and fee-
for-service Medicare populations. Remaining subgroups of 
US adults include people with private insurance, uninsured 
people, Medicaid beneficiaries without Medicare coverage, 
Medicare Advantage participants, and military forces. The 
commercially insured and fee-for-service Medicare popula-
tions account for approximately 60% of the US adult popula-
tion; the impact of possible differential prevalence in other 
subgroups is unclear.
A last important consideration in interpreting our 
estimates is that not all cases of metastatic bone disease 
are diagnosed. Patients with a poor prognosis at the time 
of cancer diagnosis might not receive tests for metastatic 
bone disease, with the rationale that they will die soon and 
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the information will not change treatment decisions. Other 
patients might develop asymptomatic metastatic bone disease 
and live with it for some time before it becomes symptomatic 
or is discovered during routine testing. This study reports 
only cases of metastatic bone disease that have come to the 
attention of health care providers and were recorded.
Despite these limitations, our data provide a recent 
perspective on prevalence of metastatic bone disease and 
increase knowledge about the distribution across cancer 
types.
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